background:

Antibody glycosylation remodeling is a technology that changes the glycosylation pattern on antibody molecules. Its advantages include enhancing the stability of antibodies, improving their pharmacokinetic properties, and enhancing their antibody-dependent cellular cytotoxicity (ADCC) activity. This technology has a wide range of applications in drug development and treatment, including the treatment of cancer, autoimmune diseases, and infectious diseases.

Human IgG sugar chain remodeling and glycosylation refer to the change of structure or properties of human immunoglobulin G (IgG) molecules, or the introduction of chemical groups or functional groups at specific positions to achieve specific functions or applications. The significance of this remodeling or coupling is to expand the application field and function of human IgG and improve its therapeutic effect or biological activity. By changing the structure or properties of IgG, drug delivery performance, immune activity, stability, etc. can be regulated to achieve better therapeutic effects or application effects.

Product Packaging:

the Rhinogen ^® TransCOUPER ™ Fucose Remodeling Kit are as follows:

Product Overview:

The Rhinogen ^® TransCOUPER ™ De-fucosylation Kit allows for efficient site-specific transglycosylation of native human IgG in a matter of hours. The Rhinogen ^® TransCOUPER ™ De-fucosylation Kit uses enzymatic remodeling technology to transglycosylate the N-glycans at the Fc terminus of antibodies, resulting in a homogenous pool of antibodies with defined glycosylation patterns (G0, G1, G2 or G2S2) and core glycosylation. The kit contains sufficient material to transglycosylate 1 mg of human IgG.

Product Source:

The enzymes in the kit are all expressed in E. coli and have a His tag.

Unit Definition:

1 mg of human IgG1 was ≥ 95% transglycosylated as determined by LC-MS.

Storage conditions:

Refrigerated transportation. After the product arrives, lmmobilized EndoS2&α1-6 Fucosidase , Microspin and Protein A purification columns should be stored at 2~8℃, and Glycosyltransferase and Glycoform G0 or G1 or G2 or G2S2 should be stored at -25~-5℃. Do not freeze lmmobilized EndoS2&α1-6 Fucosidase , Microspin and Protein A purification columns.

characteristic:

human IgG with fully glycosylated homogeneous glycoforms ;

2. Completely remove core fucose to study its effect on functional tests;

3. Achieve reliable glycan remodeling within hours.

application:

homogenous glycoforms without α1-6 linked core fucose .

principle:

Note:

1. The reagent can be used for all subclasses of human IgG. However, the reaction on IgG2 is slightly slower, and a longer incubation time may be required to obtain more than 95% transglycosylation;

2. Before use, equilibrate the lmmobilized EndoS2&α1-6 Fucosidase , Microspin and Protein A purification columns to room temperature;

3. Before centrifugation, remove the bottom cover and slightly open the top cover;

4. This product is for research and development use only.